Clinical Trial Update: Oral Resveratrol to Prevent Post-ERCP Pancreatitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for oral resveratrol to prevent post-ERCP pancreatitis. The current trial status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• Resveratrol (resveratrol)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Pancreatitis, Acute, Gastrointestinal Disease | Phase 4 | Status: UNKNOWN